FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035364235> ?p ?o ?g. }

• W2035364235 endingPage "161" @default.
• W2035364235 startingPage "160" @default.
• W2035364235 abstract "Raltegravir, the first approved HIV integrase inhibitor, has demonstrated an excellent safety and tolerability profile in several clinical trials [1] and is currently used widely as one of the key components of salvage regimens. However, the duration of clinical use is relatively short, and unknown adverse effect may occur. Here, we report one case of peritonitis associated with use of raltegravir. Abdominal symptoms appeared within 2 weeks of commencement of treatment, and raltegravir had to be stopped due to worsening of clinical condition. Case report The patient was a 49-year-old Japanese hemophiliac coinfected with HIV and hepatitis C virus (HCV). HIV-RNA was undetectable, and CD4+ cell count was above 500 cells/μl for more than 5 years under the combination of abacavir, nevirapine and lopinavir/ritonavir. In January 2009, lopinavir/ritonavir was replaced with raltegravir because of bleeding tendency related to the use of a protease inhibitor. Abacavir and nevirapine were continued, and no other drugs were modified. The patient visited the hospital on day 18 after the use of raltegravir, complaining of a gradually worsening pain in the right upper abdomen and lower chest wall for 3 days. A nonsteroidal anti-inflammatory drug was not effective, and a computed tomography (CT) scan performed 11 days after the onset of the symptom revealed contrast enhancement of the liver surface (Fig. 1a) and fatty stranding of the greater omentum (Fig. 1b), which are findings compatible with perihepatitis and peritonitis. Oral prednisone (60 mg/day for 3 days, then 30 mg/day for 3 days) was prescribed, and all the symptoms resolved immediately. However, abdominal symptoms developed again after withdrawal of prednisone, necessitating its reintroduction on day 31 at 30 mg/day. Attempts to taper prednisone led to worsening of abdominal pain and development of stomatitis, resulting in continuation of treatment at 20 mg/day. Raltegravir was switched to lopinavir/ritonavir 11 weeks after the onset of abdominal pain and, finally, all antiretroviral drugs were terminated 4 days later because of diarrhea and bleeding related to lopinavir/ritonavir. Abdominal symptoms gradually improved, and prednisone could be tapered to 10 mg/day within 2 weeks. A CT scan performed 10 days after cessation of antiretroviral therapy showed an improvement of perihepatic enhancement. C-reactive protein levels increased to 1.42 mg/dl during raltegravir use and fell to normal levels 6 days after discontinuation of raltegravir. Other laboratory data including transaminase levels showed no changes, and CD4+ cell count and HIV-RNA were stable throughout the course.Fig. 1: A computed tomography scan performed 11 days after the onset of the symptoms. A computed tomography scan shows contrast enhancement around the liver surface (a) and fatty stranding of the greater omentum (b).This is the first reported case of severe peritonitis associated with raltegravir use. Although not described here, we have experienced several other cases with similar abdominal symptoms that disappeared after raltegravir termination. Several case reports have recently described previously unknown adverse effects related to raltegravir, such as rhabdomyolysis [2] and exacerbation of depression [3]. However, to our knowledge, raltegravir-associated peritonitis has not been reported. In the BENCHMRK (Blocking integrase in treatment Experienced patients with a Novel Compound against HIV: MeRcK, MK-0518) study [1], abdominal symptoms, such as diarrhea and nausea, were noted in patients on raltegravir, and some of which might be associated with mild peritonitis. Fortunately, raltegravir-associated peritonitis seemed reversible, at least to some extent. However, the longer use of raltegravir after onset of symptoms may lead to irreversible and lethal sequelae. Cessation of antiretroviral therapy as a result of severe abdominal symptoms is a potential risk for re-emergence of acute retroviral syndrome or the further accumulation of HIV-resistant mutations. Whether the described side effects are universal or related to Asians, hemophiliacs or those who have underlying liver disease is unknown at present. Careful monitoring of abdominal symptoms and the consideration of an appropriate radiographic examination are warranted after commencement of raltegravir-containing regimens. Acknowledgements The authors thank all clinical staff of the AIDS Clinical Center. All authors contributed to the conception, design and performance of this submission. This study was supported in part by the Ministry of Health, Labour, and Welfare of Japan. All authors report no potential conflict of interests." @default.
• W2035364235 created "2016-06-24" @default.
• W2035364235 creator A5004166601 @default.
• W2035364235 creator A5016549405 @default.
• W2035364235 creator A5029414324 @default.
• W2035364235 creator A5031893415 @default.
• W2035364235 creator A5072097342 @default.
• W2035364235 creator A5077723551 @default.
• W2035364235 date "2010-01-02" @default.
• W2035364235 modified "2023-09-28" @default.
• W2035364235 title "Raltegravir-associated perihepatitis and peritonitis: a single case report" @default.
• W2035364235 cites W2021606784 @default.
• W2035364235 cites W2090612044 @default.
• W2035364235 cites W2150504993 @default.
• W2035364235 doi "https://doi.org/10.1097/qad.0b013e328333d28d" @default.
• W2035364235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19952544" @default.
• W2035364235 hasPublicationYear "2010" @default.
• W2035364235 type Work @default.
• W2035364235 sameAs 2035364235 @default.
• W2035364235 citedByCount "4" @default.
• W2035364235 countsByYear W20353642352012 @default.
• W2035364235 countsByYear W20353642352019 @default.
• W2035364235 countsByYear W20353642352020 @default.
• W2035364235 crossrefType "journal-article" @default.
• W2035364235 hasAuthorship W2035364235A5004166601 @default.
• W2035364235 hasAuthorship W2035364235A5016549405 @default.
• W2035364235 hasAuthorship W2035364235A5029414324 @default.
• W2035364235 hasAuthorship W2035364235A5031893415 @default.
• W2035364235 hasAuthorship W2035364235A5072097342 @default.
• W2035364235 hasAuthorship W2035364235A5077723551 @default.
• W2035364235 hasBestOaLocation W20353642351 @default.
• W2035364235 hasConcept C126322002 @default.
• W2035364235 hasConcept C141071460 @default.
• W2035364235 hasConcept C142462285 @default.
• W2035364235 hasConcept C159047783 @default.
• W2035364235 hasConcept C197934379 @default.
• W2035364235 hasConcept C2777182164 @default.
• W2035364235 hasConcept C2779130552 @default.
• W2035364235 hasConcept C2779298103 @default.
• W2035364235 hasConcept C2780404665 @default.
• W2035364235 hasConcept C2993143319 @default.
• W2035364235 hasConcept C3013748606 @default.
• W2035364235 hasConcept C71924100 @default.
• W2035364235 hasConcept C90924648 @default.
• W2035364235 hasConcept C98274493 @default.
• W2035364235 hasConceptScore W2035364235C126322002 @default.
• W2035364235 hasConceptScore W2035364235C141071460 @default.
• W2035364235 hasConceptScore W2035364235C142462285 @default.
• W2035364235 hasConceptScore W2035364235C159047783 @default.
• W2035364235 hasConceptScore W2035364235C197934379 @default.
• W2035364235 hasConceptScore W2035364235C2777182164 @default.
• W2035364235 hasConceptScore W2035364235C2779130552 @default.
• W2035364235 hasConceptScore W2035364235C2779298103 @default.
• W2035364235 hasConceptScore W2035364235C2780404665 @default.
• W2035364235 hasConceptScore W2035364235C2993143319 @default.
• W2035364235 hasConceptScore W2035364235C3013748606 @default.
• W2035364235 hasConceptScore W2035364235C71924100 @default.
• W2035364235 hasConceptScore W2035364235C90924648 @default.
• W2035364235 hasConceptScore W2035364235C98274493 @default.
• W2035364235 hasIssue "1" @default.
• W2035364235 hasLocation W20353642351 @default.
• W2035364235 hasLocation W20353642352 @default.
• W2035364235 hasLocation W20353642353 @default.
• W2035364235 hasOpenAccess W2035364235 @default.
• W2035364235 hasPrimaryLocation W20353642351 @default.
• W2035364235 hasRelatedWork W1568989442 @default.
• W2035364235 hasRelatedWork W1941857722 @default.
• W2035364235 hasRelatedWork W1989924554 @default.
• W2035364235 hasRelatedWork W1997115277 @default.
• W2035364235 hasRelatedWork W2124420410 @default.
• W2035364235 hasRelatedWork W2132535766 @default.
• W2035364235 hasRelatedWork W2158292961 @default.
• W2035364235 hasRelatedWork W2182164191 @default.
• W2035364235 hasRelatedWork W2269514821 @default.
• W2035364235 hasRelatedWork W2338494325 @default.
• W2035364235 hasVolume "24" @default.
• W2035364235 isParatext "false" @default.
• W2035364235 isRetracted "false" @default.
• W2035364235 magId "2035364235" @default.
• W2035364235 workType "article" @default.